Brian Low Financial Group LLC Invests $801,000 in Becton, Dickinson and Company $BDX

Brian Low Financial Group LLC bought a new position in Becton, Dickinson and Company (NYSE:BDX) during the 1st quarter, HoldingsChannel reports. The fund bought 5,095 shares of the medical instruments supplier’s stock, valued at approximately $801,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company in the 3rd quarter worth $25,000. Steph & Co. increased its position in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 65 shares during the period. SHP Wealth Management bought a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at about $26,000. Prosperity Bancshares Inc purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth about $29,000. Finally, Accredited Wealth Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 70 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the completion of the transaction, the executive vice president owned 14,272 shares of the company’s stock, valued at approximately $2,161,922.56. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,013 shares of company stock worth $593,434 over the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $147.69 on Thursday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The stock has a market capitalization of $40.70 billion, a P/E ratio of 37.39, a P/E/G ratio of 10.19 and a beta of 0.22. The company’s 50-day moving average is $148.24 and its 200 day moving average is $171.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, topping the consensus estimate of $2.77 by $0.13. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.67 billion. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. Becton, Dickinson and Company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the business posted $3.35 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.8%. Becton, Dickinson and Company’s payout ratio is currently 106.33%.

Analyst Ratings Changes

BDX has been the topic of a number of research analyst reports. Argus reduced their price target on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Weiss Ratings lowered Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. TD Cowen reduced their target price on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. Stifel Nicolaus decreased their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Finally, Piper Sandler dropped their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $181.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.